Elon Musk’s Neuralink has launched its first clinical study in Great Britain to test its brain-computer interface device.

The trial will assess the safety and performance of Neuralink’s brain chip in human volunteers with severe neurological conditions.

Regulatory approval was granted following similar trials in the United States, as the company expands its efforts to integrate advanced neurotechnology with healthcare applications.